Adrianus Johannes de Langen

14PUBLICATIONS
117CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|May 25, 2026
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer.

|May 08, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

|Mar 06, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.

Helena A Yu, Kwan Ho Tang, Aleksandra A Markovets

|Feb 04, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.

Benjamin Besse, Jessica J Lin, Lyudmila Bazhenova

|Jun 04, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.

Jonathan W Riess, Adrianus J de Langen, Santiago Ponce

Pageof 3

Frequent Collaborators

4 joint publications

Egbert Smit

3 joint publications

Jonathan W Goldman

3 joint publications

Kwan Ho Tang

3 joint publications

Jonathan W Riess